Safety and Efficacy Evaluation of Topical Moxidex Otic Solution in the Treatment of Acute Otitis Media with Otorrhea in Tympanostomy Tubes - Safety and Efficacy of Moxidex Otic Solution in AOMT

Alcon Research Ltd.0 sites1,300 target enrollmentDecember 2, 2010

Overview

No summary available.

Registry

who.int

Start Date

December 2, 2010

End Date

TBD

Last Updated

14 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•1\) At least 6 months and no more than 12 years of age at the time of enrollment
•2\) Presence of otorrhea at Visit 1 of 21 days or less in duration, visible by the parent/guardian in at least 1 ear
•3\) Presence of patent tympanostomy tube(s). Patients with obstructed tympanostomy tube(s) that cannot be cleared at the time of enrollment MUST NOT be enrolled
•4\) Will refrain from significant water immersion of the ear(s) without the use of adequate ear protection during swimming, bathing, showering, and other water\-related activities
•5\) Read and signed (by parent or guardian) the informed consent. When required by the Institutional Review Board, the child must agree to sign an approved assent form
•6\) Patient and parent/guardian mut agree to comply with the requirements of the study. Parent/guardian must agree to administer the study medication as directed, complete the required study visits, accurately complete twice daily phone calls into the IVRS system, and participate in 5 compliance phone contacts
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) no
•F.1\.2\.1 Number of subjects for this age range

•1\) Patients who have NOT been otorrhea\-free for at least seven (7\) days following tympanostomy tube surgery
•2\) Tympanostomy tubes containing antimicrobial agents or any tube longer than 2\.5 mm that my prohibit verification of tube patency
•3\) History of/or current acute or chronic non\-tube otorrhea (through existing perforation of the eardrum)
•4\) Current acute otitis externa (AOE), or malignant otitis externa (MOE) or other conditions which could interfere with evaluatio nof the study drug
•5\) Known or suspected ear infection of fungal or mycobacterial origin
•6\) History of/or active herpes simplex, vacinna or varicella infections or overt viral infections of the tympanic membrane (eg, myringitis bullosa) or ear canal. Patients with a history of/or active herpetic infections in locations other than the ear may be enrolled
•7\) Prior otologic surgery, except those confined to the tympanic membrane, within 1 year or study entry
•8\) Mastoiditis or other suppurative noninfectious disorders in the ear(s)